AstraZeneca Korea to launch fulvestrant, new treatment option for advanced breast cancer

Published: 2008-11-03 06:45:00

Updated: 2008-11-03 06:45:00

AstraZeneca Korea has announced that it will launch fulvestrant (Faslodex 250mg), a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It received approval from the nation’s food and drug authorities in October 2007.

Fulvestrant is an estrogen receptor antagonist with no agonist effects, which...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.